TRAX (First Tracks Biotherapeutics) EV-to-EBIT: (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $44.64
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, First Tracks Biotherapeutics's Enterprise Value is $1,434.91 Mil. First Tracks Biotherapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate First Tracks Biotherapeutics's EV-to-EBIT at this moment.

The historical rank and industry rank for First Tracks Biotherapeutics's EV-to-EBIT or its related term are showing as below:

TRAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.99   Med: 0   Max: 0
Current: -7.92
TRAX's EV-to-EBIT is ranked worse than
100% of 380 companies
in the Biotechnology industry
Industry Median: 15.92 vs TRAX: -7.92

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. First Tracks Biotherapeutics's Enterprise Value for the quarter that ended in Dec. 2024 was $0.00 Mil. First Tracks Biotherapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate First Tracks Biotherapeutics's Earnings Yield (Joel Greenblatt) % at this moment.

First Tracks Biotherapeutics  (NAS:TRAX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

First Tracks Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=/0
= %

First Tracks Biotherapeutics EV-to-EBIT Related Terms

First Tracks Biotherapeutics EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics EV-to-EBIT Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
EV-to-EBIT
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
EV-to-EBIT 0.00 0.00

TRAX vs AVLN, IMTX, ARDX: EV-to-EBIT Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

First Tracks Biotherapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's EV-to-EBIT falls into.


TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics EV-to-EBIT Calculation

First Tracks Biotherapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1434.914/
=

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.64
Price